Tumor characteristics differ significantly among pediatric and adolescent and young adult (AYA) patients with melanoma, with decreasing incidence rates seen among young patients with cutaneous melanoma, according to a study published online Nov. 15 in the Journal of the American Academy of Dermatology.
2025
FDA Receives BLA for RP1 and Nivolumab Combo in Advanced Melanoma
The FDA has received a BLA submission seeking the accelerated approval of RP1 plus nivolumab for the potential treatment of adult patients with advanced melanoma who have received prior treatment with a regimen that contains a PD-1 inhibitor.
Characteristics Differ for Melanomas in Children, Teens, Young Adults
TUESDAY, Nov. 26, 2024 (HealthDay News) — Tumor characteristics differ significantly among pediatric and adolescent and young adult (AYA) patients with melanoma, with decreasing incidence rates seen among young patients with cutaneous melanoma, according to a study published online Nov. 15 in the Journal of the American Academy of Dermatology.
Heart Transplant Recipients are More Susceptible to Skin Cancer
Certain factors may contribute to higher occurrences of non-melanoma skin cancer in these patients, according to a novel systemic review.